key: cord-0695403-joyj13ye authors: Herishanu, Yair; Avivi, Irit; Aharon, Anat; Shefer, Gabi; Levi, Shai; Bronstein, Yotam; Morales, Miguel; Ziv, Tomer; Shorer, Yamit; Scarfò, Lydia; Joffe, Erel; Perry, Chava; Ghia, Paolo title: Efficacy of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Chronic Lymphocytic Leukemia date: 2021-04-22 journal: Blood DOI: 10.1182/blood.2021011568 sha: 1b64c04bea98da0133829a6c0b4a0a39c9f6eb5b doc_id: 695403 cord_uid: joyj13ye Patients with chronic lymphocytic leukemia (CLL) have an increased risk for severe COVID-19 disease and mortality. The goal of this study (NCT04746092) was to determine the efficacy of COVID-19 vaccine in patients with CLL. We evaluated humoral immune responses to BNT162b2 mRNA COVID-19 vaccine in patientswith CLL and compared responses with those obtained in age-matched healthy controls. Patients received two vaccine doses, 21 days apart, and antibody titers were measured using Elecsys® Anti-SARS-CoV-2S assay after administration of the second dose. In a total of 167 patients with CLL the antibodyresponse rate was39.5%. A comparison between 52 patients with CLL and 52 sex- and aged-matched healthy controls, revealed a significantly reduced response rate among patients (52% vs 100%, respectively; adjusted odds ratio=0.010, 95% CI 0.001-0.162; p<0.001). Response rate was highest in patients who obtained clinical remissionafter treatment (79.2%), followed by 55.2% in treatment-naïveand 16% only in patients under treatment at the time of vaccination. In patients treated with either BTK inhibitors or venetoclax± anti-CD20 antibody, response rates were considerably low (16.0% and 13.6%, respectively). None of the patients exposed to anti-CD20 antibodies <12 months prior to vaccination responded. In a multivariate analysis, the independent predictors of response were younger age, females,lack of currently active treatment, IgG levels ≥550 mg/dL and IgM levels ≥40mg/dL. In conclusion,antibody-mediated response to BNT162b2 mRNA COVID-19 vaccine in patients with CLLis markedly impaired and affected by disease activity and treatment. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is a single-stranded RNA virus, which causes Coronavirus Disease 2019 (COVID-19), a disease with variable presentations, ranging from mild common cold to severe respiratory failure 1, 2 . An increased risk for severe disease and death has been noted among elderly patients and persons with preexisting medical conditions 1, 2 . The coronavirus genome encodes four main structural proteins designated: spike (S), envelope, membrane, and nucleocapsid. The virus penetrates the host through binding of the viral S protein to the angiotensinconverting enzyme 2 (ACE2) presented on oral mucosa epithelial cells and the lung alveolar type II cells 3, 4 . In general, patients with chronic lymphocytic leukemia (CLL) are predisposed to develop infections, both bacterial and viral, due to inherent immune defects related to their primary disease, and as a result of therapy 5 . The mechanisms underlying the immunodeficiency in CLL includes abnormal humoral and cellular immune responses due to quantitative and qualitative defects in immune effector cells, which may also reduce response to vaccines 6 . During the previous months of the COVID-19 pandemic, two large multicenter retrospective studies have reported high rates of severe COVID-19 disease and mortality in both untreated ("watch and wait") as well as treated patients with CLL 7, 8 . Recently, two vaccines (BNT162b2 and mRNA-1273) were approved and recommended by the FDA and EMA to prevent COVID-19 disease. BNT162b2 and mRNA-1273 are lipid nanoparticle-encapsulated mRNA-based vaccines, that encode the full length S protein of SARS-CoV-2 9, 10 . In phase III trials, these vaccines showed 94-95% efficacy in preventing symptomatic SARS-CoV-2 infection independent of age 11,12 . However, until now, hemato-oncology patients were excluded from clinical trials with COVID-19 vaccines. In this study, we evaluated antibody-mediated response to BNT162b2 mRNA COVID-19 vaccine in patients with CLL. This prospective study, conducted in the framework of the European Research Initiative on CLL (ERIC), investigated the efficacy of BNT162b2 mRNA COVID-19 vaccine in patients with CLL/small lymphocytic lymphoma (SLL) followed at the Tel-Aviv Sourasky Medical Center. The study was approved by the institutional review board and is registered in ClinicalTrials.gov, number NCT04746092. All patients provided informed consent. Patients were vaccinated through the national Israeli vaccination program. Eligibility criteria for the study included diagnosis of CLL/SLL per the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria 13 , age 18 years or older, with no known history of SARS-CoV-2 infection. The study has also included healthy volunteers, age ≥18 years, that served as a control group. Blood serum of patients with CLL/SLL and healthy controls were collected 2-3 weeks after administration of the second vaccine. The primary endpoint was the proportion of subjects acquiring anti SARS-CoV-2S antibodies. Serum samples were analyzed by using Elecsys® Anti-SARS-CoV-2S assay on the cobas e 601 (Roche Diagnostics) for the quantitative detection of antibodies, predominantly IgG, aimed at the SARS-CoV-2 spike protein receptor binding domain. This assay has a measurement range of 0.40-250 U/mL, with a concentration of <0.80 U/mL considered as negative, and ≥0.80 U/mL considered as positive. When sample results exceed the upper limit of the measuring range (reported as > 250 U/mL), samples were on-board diluted 1:10 or 1:100 when needed (>2500 U/mL for 10-fold diluted samples). To ensure that none of the patients had been recently exposed to SARS-CoV-2, we additionally tested for the presence of antibodies to SARS-CoV-2 nucleocapsid by the Elecsys® Anti-SARS-CoV-2 assay using the cobas e 601 (Roche Diagnostics). All subjects were inquired about local or systemic adverse events (AEs) that occurred within 7 days after each vaccine dose. Relevant data was extracted from the medical records and included: demographics, complete blood count, Binet stage, serum immunoglobulin (Ig) levels, mutational status of the immunoglobulin heavy chain variable (IGHV) gene (using a cut off of 98% identity to the germ-line sequence) and analyses of genomic aberrations by fluorescent in situ hybridization (FISH) 14 From December 2020 through February 2021, a total of 167 patients with CLL/SLL and 52 age and sex-matched controls, were included in this study (patient baseline demographic and disease characteristics are summarized in Table 1 Figure 1D ]. Of note, none of the patients with CLL that achieved seropositive test against the SARS-CoV-2 spike protein receptor binding domain, had anti-SARS-CoV-2 nucleocapsid antibodies. In a univariate analysis, the variables found to be significantly associated with response included ( Table 2) : younger age (≤65 years), females, early disease stage (Binet A), mutated IGHV, β-2-microglobulin (≤3.5 mg/L), untreated/off-therapy ≥12 months from the last anti-CD20 therapy, IgG levels ≥ 550 mg/dL, IgM levels ≥ 40 mg/dL and IgA levels ≥ 80 mg/dL. Treatment-naïve patients had higher response rate (55.2%, n=23 of 58) and higher antibody levels (median=1.7, IQR 0.4-136.0, Figure with venetoclax ± anti-CD20 antibodies (p=NS, Figure 2C ). Two out of the five (40%) patients that received venetoclax monotherapy achieved a positive serologic response, with relatively low antibody titers (range 2.19-4.5 U/mL). Demographic, disease-related and treatment-associated factors (including the number of prior lines) had no statistically significant impact on response rate in actively treated patients. A total of 77 patients with CLL have been previously exposed to anti-CD20 therapy; 22 within the last 12 months prior to vaccination (median 5.3 months, IQR 0.75-8.0) and 55 patients, ≥12 months before vaccination (median 53.1 months, IQR 25.5-76.8). Most patients (18/22, 81.8%) exposed to anti-CD20 antibodies <12 months prior to vaccination, received it in combination with venetoclax. The majority of patients (43/55, 78.1%) treated with anti-CD20 therapy ≥12 months prior to vaccination, received chemoimmunotherapy. None of the patients, treated with anti-CD20 antibodies (n=22) within the last 12 months has responded vs. 45.5% (n=25 of 55) of those that were exposed to anti-CD20 therapy ≥12 months prior to vaccination (aOR=37.6, 95% CI 2.2-651.3; p=<0.001). In the subgroup of patients treated with anti-CD20 antibody ≥12 months prior to vaccination, there was no association between the time that elapsed from the end of the anti-CD20 therapy and their serologic response. A particularly high response rate (79.2%) and antibody levels (median=297.6, IQR 1.2-1149.8) were observed among the 24 patients who completed treatment (mostly chemoimmunotherapy or targeted therapies) and maintained their response (CR/PR) at the time of vaccination, (Figure 2A -B, Supplementary Tables 2-3) . Serologic response rate was remarkably high in those who completed treatment beyond 12 months prior to prior to vaccination, compared to those that completed therapy within less than 12 months (94.1% vs. 50.0%, P=0.04, Supplementary Table 2 ). In a multivariate analysis ( Fifty two (31.1%) and fifty six ( Table 4 ). The systemic side effects most commonly reported after the second dose were weakness (8.6%, n=14), fever (6.6%, n=11), chills (6.0%, n=10), headache (5.4%, n=10) and muscle pain (4.8%, n=8) (Supplementary Table 4 ). No statistically significant correlation was found between local or systemic reaction and a positive serological response to the vaccine. In addition, there were no statistically significant differences in the rate of adverse events between patients that were actively treated at the time of vaccination vs those who did not. This study evaluated the serologic response to SARS-CoV-2 vaccination after a two- vaccine on the cellular immunity should be further studied in patients with CLL, to better understand its protective role, particularly in patients who failed to achieve an optimal antibody-mediated response. Indeed, both humoral and cellular responses seem to be important in this setting. However, there are several reports 35, 36 , including in non-Hodgkin's lymphoma patients that were infected with COVID19 37 , suggesting that T cell response is generally preserved in patients that have been recently treated with B cell depleting therapy. Moreover, a robust humoral response seems to be important for the achievement of a rapid clearance of COVID19 infection 37 . In addition, it remains to be established if and for how long the patients with CLL that showed an immune response to the vaccine will maintain these levels throughout time as well as if they will be able to maintain to a B-cell memory response. Only longer follow-up will tell us. In summary, the antibody-mediated response to SARS-CoV-2 vaccine in patients with Abbreviations: CI -confidence interval; FISH -Fluorescence in situ hybridization; IGHV -immunoglobulin heavy chain; P -probability value; y -years (C) Response rate in patients with CLL (n=52) and sex-and age-matched controls (n-52). (D) Anti-SARS-CoV-2 Antibody levels in patients with CLL (n=52) and sex-and age-matched controls (n-52). Characteristics of SARS-CoV-2 and COVID-19 Clinical features of patients infected with 2019 novel coronavirus in Wuhan SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein A review of the infection pathogenesis and prophylaxis recommendations in patients with chronic lymphocytic leukemia Immune defects in patients with chronic lymphocytic leukemia Outcomes of COVID-19 in patients with CLL: a multicenter international experience COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates An mRNA Vaccine against SARS-CoV-2 -Preliminary Report Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL) Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin's Lymphoma Patients Treated with Rituximab-Containing Regimens Rituximab as adjuvant to highdose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma The effect of rituximab on vaccine responses in patients with immune thrombocytopenia Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains Vaccines for the prevention against the threat of MERS-CoV Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19 Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab on Viral Load in Patients with Mild to Moderate COVID-19: A Randomized Clinical Trial Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab B-cell depletion immunotherapy in pemphigus: Effects on cellular and humoral immune responses Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19 The authors would like to thank the clinical study coordinators, nurses and lab staff at the hematology department in the Tel-Aviv Sourasky medical centre. YH and IA-Initiated the trial, designed the study analyzed data and wrote the paper. AA, GS and MM-Performed the serological testing, YB-Collected the data, SL, TZ and EJ-Analyzed the data, LS-Designed the study, CP-Wrote the paper, PG-Designed the study and wrote the paper YH reports honoraria from AbbVie, Janssen, Astra-Zeneca and Roche outside the submitted work. IA reports speaker's bureau for Gilead, Novartis, AbbeVie, Janssen and served consultant for Janssen, MSD, AbbVie, Novartis and Roche outside the submitted work, EJ-Advisory board AstraZeneca and Epizyme. PG reports grants and personal fees from AbbVie, Gilead, Janssen, Pharmacyclics, and Sunesis; personal fees from AstraZeneca, Adaptive, Arqule/MSD, BeiGene, Celgene/Juno/BMS, Lilly/Loxo, outside the submitted work. The remaining authors declare no competing financial interests.